Clinical Trial Update: A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating three doses of pegaptanib sodium for wet age-related macular degeneration was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Pegaptanib sodium (Macugen) (pegaptanib sodium)

Snippet

Sponsor: Eyetech Pharmaceuticals | Conditions: Macular Degeneration | Phase 4 | Status: TERMINATED